Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
Blood · 21.11.2024 · 144 (21) · 2169-2173
DOI: 10.1182/blood.2024025409 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, erschienen am 21.11.2024. Verfasst von Hartmut Döhner und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 282-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA.
- University of Warwick Trials Unit, Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom.
- Department of Hematology, Saint-Louis Institute for Research, Université Paris Cité, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
ORCID-Profile: Hartmut Döhner, Courtney D DiNardo, Charles Craddock, Benjamin L Ebert, Richard A Larson, Dietger Niederwieser, Christoph Röllig, Jorge Sierra, Jianxiang Wang, Agnieszka Wierzbowska, Andrew H Wei, Bob Löwenberg
Zitieren
APA
Döhner, H., DiNardo, C. D., Appelbaum, F. R., Craddock, C., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., Larson, R. A., Levine, R. L., Miyazaki, Y., Niederwieser, D., Ossenkoppele, G., Röllig, C., Sierra, J., Stein, E. M., Tallman, M. S., Tien, H. F., …, & Löwenberg, B. (2024). Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood, 144(21), 2169-2173. https://doi.org/10.1182/blood.2024025409
Vancouver
Döhner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144(21):2169-2173. doi:10.1182/blood.2024025409
BibTeX
@article{Dhner2024,
author = {Döhner, Hartmut and DiNardo, Courtney D and Appelbaum, Frederick R and Craddock, Charles and Dombret, Hervé and Ebert, Benjamin L and Fenaux, Pierre and Godley, Lucy A and Hasserjian, Robert P and Larson, Richard A and Levine, Ross L and Miyazaki, Yasushi and Niederwieser, Dietger and Ossenkoppele, Gert and Röllig, Christoph and Sierra, Jorge and Stein, Eytan M and Tallman, Martin S and Tien, Hwei-Fang and Wang, Jianxiang and Wierzbowska, Agnieszka and Wei, Andrew H and Löwenberg, Bob},
title = {Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations},
journal = {Blood},
year = {2024},
volume = {144},
number = {21},
pages = {2169--2173},
doi = {10.1182/blood.2024025409}
}
EUVIMED